首页> 美国政府科技报告 >Novel Leishmania and Malaria Potassium Channels: Candidate Therapeutic Targets
【24h】

Novel Leishmania and Malaria Potassium Channels: Candidate Therapeutic Targets

机译:新型利什曼原虫和疟疾钾通道:候选治疗靶点

获取原文

摘要

Chemotherapy against Arthropod-transmitted parasitic diseases is increasingly limited by the emergence of drug resistance. Development of new drugs has been slow, emphasizing the need for better, rational anti-parasitic drug discovery. Here we report our discovery of two new potassium ion (K+) channel genes in the genome databases of Plasmodium falciparum. MAJOR FINDINGS: To date, we have cloned genes encoding 10 potential K+ channel genes (2-each for F. falciparum, T. gondii, and 3 each for L. major and T. cruzi). Using a combination of cultured mammalian cells and Xenopus oocytes for heterologous expression we have evidence that 2 channels from malaria PFK1 & PFK22) and Leishmania LMK1 & LMK2) generate K+-selective conductances that are sensitive to block by antimalaria drugs chloroquine, quinidine and the K- channel blocker trifluoroperazine. Antisera against PFKI and PFK2 recognize appropriately sized proteins from P. Falciparum. Immunofluorescence of malaria- infected erythrocytes shows that PFK1 islocalized the host cell membrane while PFK2 is primarily associated with the parasite. We also showed that a series of K-channel blockers was capable of killing cultured malaria. Our results provide the first report of a cloned ion channel from an intracellular human parasite. Moreover, electrophysiology confirms their identity as K+ channels and pharmacology supports their potential as targets for drug therapy.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号